Pugionium cornutum extract with effect of treating gastroparesis as well as preparation method and application of pugionium cornutum extract
The preparation of extracts by cold soaking of the mustard plant solved the problem of gastroparesis treatment, significantly improved gastric emptying and feces quality, and demonstrated the effective therapeutic effect on gastroparesis.
Patent Information
- Application Number
- CN202411200202.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-08-29
AI Technical Summary
Gastroparesis is a gastrointestinal motility disorder that affects the quality of life of patients. The existing technology has not yet effectively solved its treatment method, especially the cause of primary gastroparisalis is unclear, and secondary gastroparesis is in diabetes. Common in patients, affecting food absorption and blood sugar regulation.
Sand Mustard extract was prepared by cold soaking, filtration, extraction, rotary evaporation and freeze-drying of the sarcoside plants, and their efficacy in treating gastroparesis was verified by atropine-induced mouse model. Specific steps include drying fresh mustard, cutting, soaking with ethanol, concentrating with rotary evaporation, extraction and freeze-drying to obtain the ethyl acetate phase of the mustard ethanol extract of the mustard.
Effectively improving gastroparesis caused by atropine significantly improved the gastric emptying speed and feces quality of mice, reduced the gastric pigment residue and small intestinal propulsion rate, and demonstrated the potential for treating gastroparesis.
Smart Images

Figure CN118924804A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of plant extracts, and in particular relates to a sand mustard extract with the efficacy of treating gastroparesis, and a preparation method and application thereof. Background Art
[0002] Gastrointestinal health is an important prerequisite for people's quality of life. Gastroparesis (GP) is a gastrointestinal motility disorder, which refers to delayed gastric emptying in the absence of mechanical obstruction. GP has a serious impact on the quality of life of patients. Common symptoms include early satiety, anorexia, malnutrition, etc. GP can be divided into two types according to the cause: primary and secondary. Primary gastric GP often occurs in young women. Clinically, chronic gastroparesis is more common, with persistent and recurrent symptoms for months or even more than 10 years. The cause of primary GP is still unclear. Secondary GP, mainly diabetic gastroparesis, accounts for about 30%. Postprandial hypoglycemia may be a feature of gastroparesis in diabetic patients treated with insulin due to delayed food absorption. Although slowed gastric emptying rarely leads to life-threatening complications in the case of long-standing diabetes and does not increase mortality, it increases the risk of electrolyte imbalance and hypoglycemia or hyperglycemia. GP should also be considered as a potential mechanism in patients with brittle diabetes.
[0003] Pugionium cornutum (L.) Gaertn is a plant of the genus Pugionium in the family Cruciferae. Pugionium cornutum is distributed in Northeast China, North China, Northwest China and other places. Pugionium cornutum can not only be used as an edible vegetable, but also has considerable medicinal value. It is recorded in the Chinese Herbal Medicine Dictionary that the whole plant or root of Pugionium cornutum can be used as medicine. The whole plant can promote qi, relieve pain, digest food and detoxify, so it is mainly used to treat indigestion, chest and rib distension and food poisoning; Pugionium cornutum also occupies a unique position in Mongolian medicine. It can detoxify and digest food, stop vomiting and diarrhea, and treat headaches, joint pain, blurred vision, stomach distension and stomach pain, and mental confusion. It has the effects of promoting qi, relieving pain, digesting food and detoxifying. It is often used for chest and rib distension, indigestion, and food poisoning. Moreover, the root system of Pugionium cornutum is very developed, with a strong absorption capacity, which can adapt well to the arid environment of the desert and play an effective role in preventing wind and fixing sand. Therefore, Pugionium cornutum is a plant with great potential. Summary of the invention
[0004] In order to solve the above technical problems, the present invention proposes a sand mustard extract with the efficacy of treating gastroparesis, and a preparation method and application thereof. The sand mustard extract is prepared using sand mustard as a raw material through cold soaking, filtration, extraction, rotary evaporation and freeze-drying. The stool consistency, gastric emptying and small intestinal propulsion experiments on atropine-induced gastroparesis mouse model are used to verify the effect of the prepared sand mustard extract in treating gastroparesis.
[0005] To achieve the above object, the present invention provides a method for preparing a spatholobi extract having the efficacy of treating gastroparesis, comprising the following steps:
[0006] (1) drying and chopping fresh sand mustard to obtain pretreated sand mustard;
[0007] (2) the pretreated sand mustard described in step (1) is mixed with ethanol and soaked for the first time to obtain a first filtrate and the sand mustard after soaking, the first filtrate is concentrated by rotary evaporation to 1 / 10 of the original volume, and a first concentrated filtrate is obtained; the sand mustard after soaking is mixed with ethanol and soaked for the second time to obtain a second filtrate and the sand mustard after the second soaking, the second filtrate is concentrated by rotary evaporation to 1 / 10 of the original volume, and a second concentrated filtrate is obtained;
[0008] (3) combining the first concentrated filtrate in step (2) and the second concentrated filtrate in step (2), filtering, and concentrating by rotary evaporation to a paste to obtain a primary extract of Psoralea corylifolia;
[0009] (4) dissolving the primary extract of the sand mustard in step (3) in water, extracting with petroleum ether, dichloromethane and ethyl acetate in sequence, and collecting the ethyl acetate extract;
[0010] (5) The ethyl acetate extract in step (4) is concentrated by rotary evaporation to a paste, frozen, and vacuum freeze-dried to obtain a sand mustard extract.
[0011] Preferably, the drying temperature in step (1) is 40 to 60° C., and the drying time is 24 to 48 hours.
[0012] Preferably, the mass ratio of the pretreated sand mustard and ethanol mixed in step (2) is 1:10, and the volume fraction of the ethanol is 95% to 98%; the temperature of the first soaking in step (2) is 20 to 30°C, and the time of the first soaking is 48 to 72 hours.
[0013] Preferably, the mass ratio of the soaked sand mustard and ethanol in step (2) is 1:5, and the volume fraction of the ethanol is 95% to 98%; the temperature of the second soaking in step (2) is 20 to 30°C, and the time of the second soaking is 44 to 60 hours.
[0014] Preferably, the filtration in step (3) is reduced pressure filtration; the rotation speed of the rotary evaporation concentration in step (3) is 40 to 80 rpm, the temperature of the rotary evaporation concentration is 35 to 50° C., and the time of the rotary evaporation concentration is 2 to 6 hours.
[0015] Preferably, in step (4), the mass ratio of the primary extract of Psoralea corylifolia to water is (1-1.5):(1-3); and the temperature of the water is 40-60°C.
[0016] Preferably, the temperature of the freezing treatment in step (5) is -75 to -85°C, and the time of the freezing treatment is 2 to 4 hours.
[0017] Preferably, the temperature of the vacuum freeze drying in step (5) is -55 to -65°C, the time of the vacuum freeze drying is 68 to 76 hours, and the vacuum degree of the vacuum freeze drying is 0.3 to 0.8 mBar.
[0018] The invention also provides the sand mustard extract prepared by the preparation method.
[0019] The present invention also provides a sand mustard extract prepared by the preparation method or application of the sand mustard extract in preparing a drug for treating gastroparesis.
[0020] Compared with the prior art, the present invention has the following advantages and technical effects:
[0021] The invention provides a preparation method of a sand mustard extract, using ethanol with a volume fraction of 95% to 98%, extracting sand mustard ethanol extract (EPC) by cold soaking method, and then extracting EPC by using petroleum ether, dichloromethane, ethyl acetate and water in sequence after rotary evaporation concentration, and finally freeze-drying to obtain the sand mustard ethanol extract ethyl acetate phase, which is the final sand mustard extract (EAEPC). Mouse experiments have proved that it can effectively improve atropine-induced gastroparesis (GP) and has the potential to treat gastric GP. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0023] Figure 1 This is a statistical chart of gastrointestinal transit time of mice in the stool quality and stool frequency experiment;
[0024] Figure 2 This is a statistical chart of the number of feces particles excreted by mice in the stool quality and frequency experiment within 8 hours;
[0025] Figure 3 This is a statistical chart of the quality of defecation of mice in the 8-hour defecation experiment;
[0026] Figure 4 This is a statistical chart of the pigment residue rate in the stomach of mice in the gastric emptying experiment;
[0027] Figure 5 This is a statistical chart of the small intestinal propulsion rate of mice during small intestinal propulsion. DETAILED DESCRIPTION
[0028] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0029] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0030] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0031] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to the skilled artisan. The present invention description and examples are exemplary only.
[0032] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0033] Example 1
[0034] (1) drying fresh sand mustard at 50°C for 36 hours and cutting into pieces to obtain pretreated sand mustard;
[0035] (2) The pretreated sand mustard was mixed with 95% ethanol in a mass ratio of 1:10, and the mixture was first soaked at 25°C for 60 hours to obtain a first filtrate and the soaked sand mustard. The first filtrate was concentrated by rotary evaporation at a speed of 60 rpm and a temperature of 42°C for 4 hours to 1 / 10 of the original volume to obtain a first concentrated filtrate; the soaked sand mustard was mixed with 95% ethanol in a mass ratio of 1:5, and the mixture was second soaked at 25°C for 52 hours to obtain a second filtrate and the second soaked sand mustard. The second filtrate was concentrated by rotary evaporation at a speed of 60 rpm and a temperature of 42°C for 4 hours to 1 / 10 of the original volume to obtain a second concentrated filtrate;
[0036] (3) combining the first concentrated filtrate and the second concentrated filtrate, filtering under reduced pressure at a speed of 60 rpm and a temperature of 42° C. by rotary evaporation and concentrating for 4 h until the extract is in a paste form;
[0037] (4) dissolving the primary extract of the sand mustard in step (3) in 50° C. water, wherein the mass ratio of the primary extract of the sand mustard to water is 1.25:2, extracting with petroleum ether, dichloromethane, and ethyl acetate in sequence, and collecting the ethyl acetate extract;
[0038] (5) The ethyl acetate extract in step (4) was concentrated by rotary evaporation at a rotation speed of 60 rpm and a temperature of 42° C. for 4 h to a paste, and then frozen at -80° C. for 3 h, and vacuum freeze-dried at -60° C. and 0.5 mBar for 72 h to obtain a sand mustard extract.
[0039] Example 2
[0040] (1) drying fresh sand mustard at 40° C. for 48 h, and cutting into pieces to obtain pretreated sand mustard;
[0041] (2) The pretreated sand mustard was mixed with 96% ethanol by volume in a mass ratio of 1:10, and the mixture was first soaked at 20°C for 72 hours to obtain a first filtrate and the soaked sand mustard. The first filtrate was concentrated by rotary evaporation at a speed of 40 rpm and a temperature of 35°C for 6 hours to 1 / 10 of the original volume to obtain a first concentrated filtrate; the soaked sand mustard was mixed with 96% ethanol by volume in a mass ratio of 1:5, and the mixture was second soaked at 20°C for 60 hours to obtain a second filtrate and the second soaked sand mustard. The second filtrate was concentrated by rotary evaporation at a speed of 40 rpm and a temperature of 35°C for 6 hours to 1 / 10 of the original volume to obtain a second concentrated filtrate;
[0042] (3) combining the first concentrated filtrate and the second concentrated filtrate, filtering under reduced pressure at a speed of 40 rpm and a temperature of 35° C. by rotary evaporation and concentrating for 6 h until the extract is in a paste form;
[0043] (4) dissolving the primary extract of the sand mustard in step (3) in 40° C. water, with the mass ratio of the primary extract of the sand mustard to water being 1:3, extracting with petroleum ether, dichloromethane, and ethyl acetate in sequence, and collecting the ethyl acetate extract;
[0044] (5) The ethyl acetate extract in step (4) was concentrated by rotary evaporation at a rotation speed of 40 rpm and a temperature of 35° C. for 6 h to a paste, and then frozen at -75° C. for 2 h, and then vacuum freeze-dried at -55° C., 0.3 mBar, for 76 h to obtain a sand mustard extract.
[0045] Example 3
[0046] (1) drying fresh sand mustard at 60° C. for 24 h and cutting into pieces to obtain pretreated sand mustard;
[0047] (2) The pretreated sand mustard was mixed with 98% ethanol by volume in a mass ratio of 1:10, and soaked for the first time at 30°C for 48 hours to obtain a first filtrate and the soaked sand mustard. The first filtrate was concentrated by rotary evaporation at a speed of 80 rpm and a temperature of 50°C for 2 hours to 1 / 10 of the original volume to obtain a first concentrated filtrate; the soaked sand mustard was mixed with 98% ethanol by volume in a mass ratio of 1:5, and soaked for the second time at 30°C for 44 hours to obtain a second filtrate and the second soaked sand mustard. The second filtrate was concentrated by rotary evaporation at a speed of 80 rpm and a temperature of 50°C for 2 hours to 1 / 10 of the original volume to obtain a second concentrated filtrate;
[0048] (3) combining the first concentrated filtrate and the second concentrated filtrate, filtering under reduced pressure at a speed of 80 rpm and a temperature of 50° C. by rotary evaporation and concentrating for 2 h until the extract is in a paste form;
[0049] (4) dissolving the primary extract of the sand mustard in step (3) in 60° C. water, with the mass ratio of the primary extract of the sand mustard to water being 1:1, extracting with petroleum ether, dichloromethane, and ethyl acetate in sequence, and collecting the ethyl acetate extract;
[0050] (5) The ethyl acetate extract in step (4) was concentrated by rotary evaporation at a rotation speed of 80 rpm and a temperature of 50° C. for 2 h to a paste, and then frozen at -85° C. for 2 h, and vacuum freeze-dried at -65° C. and 0.8 mBar for 68 h to obtain a sand mustard extract.
[0051] Experimental example
[0052] The mass of the pretreated sand mustard described in Example 1 was weighed and recorded as M (g). The petroleum ether extract, dichloromethane extract, ethyl acetate extract and water extract prepared in step (4) of Example 1 were taken; they were concentrated by rotary evaporation at 60 rpm and 42° C. for 4 h to a paste, and then frozen at -80° C. for 3 h, and vacuum freeze-dried at -60° C. and 0.5 mBar for 72 h to obtain the petroleum ether extract, dichloromethane extract, ethyl acetate extract, i.e. the sand mustard extract (EAEPC) and the water extract.
[0053] Weigh the EAEPC and calculate the mass of the EAEPC as m (g).
[0054] The extraction rate E was calculated according to the following formula: E = m / M x 100%.
[0055] 1. Test of EAEPC's effect on GP
[0056] The effect of EAEPC on GP was verified by the mouse stool frequency and quality test, gastric emptying, and small intestinal propulsion test. After one week of adaptive feeding, 60 mice were randomly divided into 6 groups (n=10): normal control group (CG), model group (AG), mosapride positive group (MG), EAEPC low-dose group (EAEPC-L), EAEPC medium-dose group (EAEPC-M), and EAEPC high-dose group (EAEPC-H).
[0057] The EAEPC-L group calculated the dosage of mice based on the dosage of 10g / 60kg adult of sand mustard, and the dosages of EAEPC-M and EAEPC-H were 2X and 4X respectively. The dosage X calculation formula is as follows:
[0058] X = (10 / 60) × 9.61 × E, where 9.61 is the conversion factor for mouse and human dosage.
[0059] The six groups were gavaged for 16 days. CG and AG were gavaged with normal saline, MG was gavaged with 2 mg / kg mosapride, and EAEPC-L, EAEPC-M, and EAEPC-H were gavaged with X, 2X, and 3X EAEPC dissolved in normal saline, respectively.
[0060] Experiment on stool frequency and quality: After oral gavage on the 7th day, all mice were fasted for 16 hours, and 6 mice were randomly picked from each group and placed in a cage with white A4 paper. CG and AG were gavaged with normal saline, MG was gavaged with 2 mg / kg mosapride, EAEPC-L, EAEPC-M, and EAEPC-H were gavaged with X, 2X, and 3X EAEPC dissolved in normal saline, respectively. After 30 minutes, 0.5 mg / kg atropine was intraperitoneally injected according to the weight of the mice, and 50 minutes later, 0.2 mL ink was gavaged. The other 4 mice were treated the same as above.
[0061] The time of the first black feces excretion of the mice, the number and weight of feces excreted by the mice within 8 hours were recorded respectively.
[0062] Gastric emptying experiment: After the mice had defecated once, they were gavaged for 7 days. After fasting for 16 hours, CG and AG were gavaged with normal saline, MG was gavaged with 2 mg / kg mosapride, and EAEPC-L, EAEPC-M, and EAEPC-H were gavaged with X, 2X, and 4X EAEPC dissolved in normal saline, respectively. 30 minutes after gavage, 0.5 mg / kg of atropine was injected intraperitoneally according to the weight of the mice. 50 minutes later, 0.2 mL, 20 g / kg dextran blue-2000 was gavaged. 70 minutes later, the mice were dissected. The pigment in the mouse stomach was dissolved with distilled water. At the same time, 0.2 mL, 20 g / kg dextran blue-2000 dissolved in distilled water was used as a reference. The absorbances were measured using an enzyme marker and the values were b and B, respectively. Calculate the residual rate of pigment in the mouse stomach. The calculation formula for the residual rate of pigment in the mouse stomach is as follows:
[0063] Pigment residual rate in the stomach = b / B × 100%.
[0064] Intestinal propulsion experiment: Take out the mouse intestine, record the pigment propulsion length l and the small intestine length L to get the small intestine propulsion rate. The formula is as follows:
[0065] Small intestinal propulsion rate = l / L×100%.
[0066] The results of the mouse stool frequency and stool quality experiment are as follows Figure 1 , Figure 2 and Figure 3 As shown in the figure, the results of the gastric emptying and small intestinal propulsion rate experiments are as follows Figure 4 and Figure 5 Obviously, after atropine modeling, the gastrointestinal transit time and the residual rate of pigment in the stomach of the AG group increased significantly, and the fecal mass of mice at 8 hours, the number of feces particles of mice at 8 hours, and the small intestinal propulsion rate decreased significantly, indicating that the modeling was successful. Figure 1 As shown in the results, the three EAEPC groups had a certain therapeutic effect on the GP model in terms of gastrointestinal transit time, and the EAEPC-H group had the best effect. Figure 2 As shown in the figure, only the EAEPC-M group had a significant therapeutic effect on GP in terms of the number of fecal particles in mice at 8 hours. Figure 3 As shown in the 8-hour defecation quality of mice, all three EAEPC groups had significant therapeutic effects on GP, among which EAEPC-M had the best therapeutic effect. Figure 4 As shown in the table, the three groups of EAEPC showed a therapeutic effect on GP, and EAEPC-L had the best therapeutic effect. Figure 5 As shown in the data, the small intestinal propulsion rate and the three EAEPC groups had therapeutic effects on GP, with EAEPC-L having the best therapeutic effect and EAEPC-M having a similar effect.
[0067] 2. SPSSAU comprehensive evaluation to select the optimal dose of EAEPC
[0068] The optimal dose for each indicator is different, so other means are needed to evaluate and select the optimal dose.
[0069] First, the five indicators in the stool frequency and stool quality experiment, gastric emptying, and small intestinal propulsion experiment, namely, gastrointestinal transit time, 8-hour mouse feces mass, 8-hour mouse feces particle number, gastric pigment residue rate, and small intestinal propulsion rate, were processed into positive and negative dimensions. The results are shown in Table 1.
[0070] Table 1 The positive and negative dimensionalization results of the five index results in the mouse stool frequency and stool quality test, gastric emptying, and small intestinal propulsion test
[0071]
[0072] Secondly, the coupling coordination model is used to process the dimensionalized data, and the results are shown in Table 2.
[0073] Table 2 Results of coupling coordination model processing small experimental data into positive and negative dimensions
[0074]
[0075]
[0076] Finally, the rank sum ratio (RSR) model was used to directly process the raw data. Among them, gastrointestinal transit time and gastric pigment residue rate were low-quality indicators, while 8-hour mouse feces weight, 8-hour mouse feces pellet number, and small intestinal propulsion rate were high-quality indicators. The results are shown in Table 3.
[0077] Table 3 Results of the rank sum ratio (RSR) model in processing mouse experimental data
[0078]
[0079] Combining the results of the two models, the gastrointestinal motility of mice in the EAEPC-M group was the strongest, that is, when the dosage of EAEPC was 2X, EAEPC had the best therapeutic effect on the atropine-induced gastroparesis model in mice. The present invention prepared EAEPC by cold soaking, extraction, rotary evaporation, and freeze drying, and verified its therapeutic effect through experiments on stool quality, gastric emptying, and small intestinal propulsion in mice.
[0080] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. A method for preparing a spatholobi extract having the efficacy of treating gastroparesis, characterized in that: The following steps are involved: (1) drying and chopping fresh sand mustard to obtain pretreated sand mustard; (2) the pretreated sand mustard described in step (1) is mixed with ethanol and soaked for the first time to obtain a first filtrate and the sand mustard after soaking, the first filtrate is concentrated by rotary evaporation to 1 / 10 of the original volume, and a first concentrated filtrate is obtained; the sand mustard after soaking is mixed with ethanol and soaked for the second time to obtain a second filtrate and the sand mustard after the second soaking, the second filtrate is concentrated by rotary evaporation to 1 / 10 of the original volume, and a second concentrated filtrate is obtained; (3) combining the first concentrated filtrate in step (2) and the second concentrated filtrate in step (2), filtering, and concentrating by rotary evaporation to a paste to obtain a primary extract of Psoralea corylifolia; (4) dissolving the primary extract of the sand mustard in step (3) in water, extracting with petroleum ether, dichloromethane and ethyl acetate in sequence, and collecting the ethyl acetate extract; (5) The ethyl acetate extract in step (4) is concentrated by rotary evaporation to a paste, frozen, and vacuum freeze-dried to obtain a sand mustard extract.
2. The preparation method according to claim 1, characterized in that: The drying temperature in step (1) is 40 to 60° C., and the drying time is 24 to 48 hours.
3. The preparation method according to claim 1, characterized in that: The mass ratio of the pretreated sand mustard and ethanol mixed in step (2) is 1:10, and the volume fraction of the ethanol is 95% to 98%; the temperature of the first soaking in step (2) is 20 to 30° C., and the time of the first soaking is 48 to 72 hours.
4. The preparation method according to claim 1, characterized in that: The mass ratio of the soaked sand mustard and ethanol in step (2) is 1:5, and the volume fraction of the ethanol is 95% to 98%; the temperature of the second soaking in step (2) is 20 to 30° C., and the time of the second soaking is 44 to 60 hours.
5. The preparation method according to claim 1, characterized in that: The filtration in step (3) is reduced pressure filtration; the rotation speed of the rotary evaporation concentration in step (3) is 40 to 80 rpm, the temperature of the rotary evaporation concentration is 35 to 50° C., and the time of the rotary evaporation concentration is 2 to 6 hours.
6. The preparation method according to claim 1, characterized in that: The mass ratio of the primary extract of Psoralea corylifolia to water in step (4) is (1-1.5):(1-3); the temperature of the water is 40-60°C.
7. The preparation method according to claim 1, characterized in that: The temperature of the freezing treatment in step (5) is -75 to -85°C, and the time of the freezing treatment is 2 to 4 hours.
8. The preparation method according to claim 1, characterized in that: The temperature of the vacuum freeze drying in step (5) is -55 to -65°C, the time of the vacuum freeze drying is 68 to 76 hours, and the vacuum degree of the vacuum freeze drying is 0.3 to 0.8 mBar.
9. The extract of Psoralea corylifolia obtained by the preparation method according to any one of claims 1 to 8.
10. Use of the extract of Psoralea corylifolia obtained by the preparation method according to any one of claims 1 to 8 or the extract of Psoralea corylifolia according to claim 9 in the preparation of a drug for treating gastroparesis.
Citation Information
Patent Citations
Cornutcd pugionium extractive and application thereof
CN101816696A
